Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention - Ray,M.J.; Walters,D.L.; Bett,N. (Catheter Cardiovasc Interv, 2004)